论文部分内容阅读
2010版我国《慢性乙型肝炎防治指南》指出慢性乙型肝炎(chronic hepatitis B,CHB)的治疗关键是抗病毒治疗。临床上由于抗病毒药物的耐药性和停药后病毒反弹的风险,大部分患者需要长期甚至终身服药,以达到持久抑制病毒复制的目的。而长期用药则会带来药物相关不良反应。实现CHB患者的治疗目标需要对患者进行长期管理,包括疗效、耐药风险、患者依从性、安全性等,其中安全性是核苷(酸)
2010 version of our “Guide to Prevention and Treatment of Chronic Hepatitis B” pointed out that the treatment of chronic hepatitis B (CHB) is the key anti-virus treatment. Clinically due to the resistance of antiviral drugs and withdrawal of the virus after the risk of withdrawal, most patients need long-term or even lifelong medication in order to achieve the purpose of lasting inhibition of viral replication. Long-term medication will bring about drug-related adverse reactions. To achieve the goal of CHB patients need long-term management of patients, including efficacy, risk of drug resistance, patient compliance, safety and so on, of which safety is nucleoside (acid)